Long-term use of proton-pump inhibitor therapy

Gastroenterology and Hepatology

Volumn 4, Issue 5, 2008, Pages 322-325

  Metz, David C ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; DIAZEPAM; ESOMEPRAZOLE; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; THEOPHYLLINE; WARFARIN;

ACHLORHYDRIA; ANAPHYLAXIS; COLITIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG INDICATION; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERGASTRINEMIA; INTERSTITIAL NEPHRITIS; LIVER DISEASE; LIVER TOXICITY; MAINTENANCE THERAPY; NEPHROTOXICITY; NOTE; OSTEOPOROSIS; RISK BENEFIT ANALYSIS; RISK FACTOR; STOMACH DISEASE; STOMACH GLAND POLYP; SYMPTOMATOLOGY; TREATMENT DURATION;

EID: 44449158612     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (4)

1. Metz DC. Proton pump inhibitor therapy: safety issues. In: Howden CW, ed. Advances in Digestive Disease. Bethesda, Md: AGA Institute Press; 2007:3-14.
2. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947-2953.
3. Bergman MP, Klinkenberg-Knol EC, Faller G, Aar A, Lakhai W, et al. Long-term acid suppression by omeprazole in gastro-oesophageal reflux disease patients does not lead to anti-gastric autoantibody production. Aliment Pharmacol Ther. 2005;21:977-983.
4. Fennerty MB. Review article: alternative approaches to the long-term management of GERD. Aliment Pharmacol Ther. 2005;22 (Suppl 3):39-44.